BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19939923)

  • 1. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
    Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
    J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
    Ooms M; Letko M; Binka M; Simon V
    PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
    Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
    PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
    Ooms M; Letko M; Simon V
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping Region of Human Restriction Factor APOBEC3H Critical for Interaction with HIV-1 Vif.
    Nakashima M; Tsuzuki S; Awazu H; Hamano A; Okada A; Ode H; Maejima M; Hachiya A; Yokomaku Y; Watanabe N; Akari H; Iwatani Y
    J Mol Biol; 2017 Apr; 429(8):1262-1276. PubMed ID: 28336404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
    J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
    Zhen A; Du J; Zhou X; Xiong Y; Yu XF
    PLoS One; 2012; 7(7):e38771. PubMed ID: 22859935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif.
    Zhao K; Du J; Rui Y; Zheng W; Kang J; Hou J; Wang K; Zhang W; Simon VA; Yu XF
    Cell Cycle; 2015; 14(6):838-47. PubMed ID: 25590520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.
    Wang J; Becker JT; Shi K; Lauer KV; Salamango DJ; Aihara H; Shaban NM; Harris RS
    J Mol Biol; 2019 Dec; 431(24):5019-5031. PubMed ID: 31628948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
    Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
    J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection.
    Gourraud PA; Karaouni A; Woo JM; Schmidt T; Oksenberg JR; Hecht FM; Liegler TJ; Barbour JD
    Hum Immunol; 2011 Mar; 72(3):207-12. PubMed ID: 21167246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
    Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
    J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Davis RW; York IA; Zheng YH
    J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.
    Ooms M; Majdak S; Seibert CW; Harari A; Simon V
    J Virol; 2010 Aug; 84(16):7961-9. PubMed ID: 20519396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.